Securian Asset Management Inc. Sells 3,005 Shares of Biogen Inc. $BIIB

Securian Asset Management Inc. trimmed its holdings in Biogen Inc. (NASDAQ:BIIB) by 43.2% in the fourth quarter, HoldingsChannel reports. The fund owned 3,945 shares of the biotechnology company’s stock after selling 3,005 shares during the period. Securian Asset Management Inc.’s holdings in Biogen were worth $694,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in BIIB. Orion Porfolio Solutions LLC lifted its holdings in shares of Biogen by 6,828.4% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after acquiring an additional 509,809 shares during the last quarter. Caisse de depot et placement du Quebec lifted its holdings in shares of Biogen by 718.2% in the 3rd quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock worth $79,741,000 after acquiring an additional 499,676 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Biogen by 30.7% in the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock worth $248,809,000 after acquiring an additional 418,776 shares during the last quarter. Alyeska Investment Group L.P. lifted its holdings in shares of Biogen by 66.1% in the 3rd quarter. Alyeska Investment Group L.P. now owns 845,277 shares of the biotechnology company’s stock worth $118,406,000 after acquiring an additional 336,504 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Biogen by 425.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 348,404 shares of the biotechnology company’s stock worth $48,804,000 after acquiring an additional 282,084 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen said diranersen produced robust tau reductions and showed cognitive benefit signals in early Alzheimer’s disease, supporting plans to move the program into Phase 3 development. Biogen Shares Jump 10% After Advancing Alzheimer’s Tau Drug
• Positive Sentiment: Several analysts remained upbeat after the CELIA data, with buy ratings and price-target support implying Wall Street sees the tau program as more de-risked than before. Biogen Buy Rating Reiterated as CELIA Phase 2 Diranersen Data De-Risk Tau Strategy and Support Unchanged $237 Price Target
• Positive Sentiment: Biogen also completed its acquisition of Apellis Pharmaceuticals, which could strengthen near-term growth by adding commercial products and broadening the company’s revenue base. Biogen Completes Acquisition of Apellis Pharmaceuticals
• Neutral Sentiment: Biogen’s Alzheimer’s pipeline remains in focus, with additional coverage noting the company still appears likely to win approval for a subcutaneous Leqembi formulation, though the FDA timeline has been delayed. Biogen’s ‘Leqembi’ Subcutaneous Approval Still Likely Despite FDA Delay, RBC Says
• Negative Sentiment: The stock also faced some skepticism because CELIA missed its primary endpoint, which is tempering enthusiasm even as investors react positively to the biomarker and cognitive signals. Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

Biogen Trading Down 6.4%

NASDAQ:BIIB opened at $191.37 on Friday. The company has a fifty day moving average of $185.15 and a 200 day moving average of $179.24. Biogen Inc. has a 52 week low of $119.18 and a 52 week high of $205.97. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $28.25 billion, a P/E ratio of 20.53, a P/E/G ratio of 1.80 and a beta of 0.19.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the business posted $3.02 EPS. The firm’s revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, research analysts predict that Biogen Inc. will post 14.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and increased their target price for the company from $185.00 to $225.00 in a report on Wednesday, April 22nd. Tudor Pickering set a $201.00 price target on Biogen in a research note on Monday, February 9th. Truist Financial decreased their price target on Biogen from $193.00 to $189.00 and set a “hold” rating on the stock in a research note on Monday, April 13th. Mizuho lifted their price target on Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Finally, Argus raised Biogen to a “hold” rating in a research note on Thursday, April 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $214.23.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.